Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA.
Ultrasound Obstet Gynecol. 2009 Nov;34(5):572-8. doi: 10.1002/uog.7435.
To compare women undergoing magnetic resonance-guided focused ultrasound (MRgFUS) to a group of contemporaneously recruited women undergoing total abdominal hysterectomy. Patient demographics, safety parameters, quality of life outcomes and disability measures are reported.
One hundred and nine women were recruited in seven centers for MRgFUS treatment and 83 women who underwent abdominal hysterectomy were recruited in seven separate centers to provide contemporaneous assessment of safety. The adverse-event profile and disability parameters were prospectively assessed. Patients were also screened at baseline and at 1, 3 and 6 months using the SF-36 health survey questionnaire.
There were no life-threatening adverse events in either group. Overall, the number of significant clinical complications and adverse events was lower in women in the MRgFUS group compared to women undergoing hysterectomy. MRgFUS was associated with significantly faster recovery, including resumption of usual activities. At 6 months of follow-up, there were four (4%) treatment failures in the MRgFUS arm. Regarding SF-36 subscale scores, at 6 months there was improvement in all SF-36 subscales for both treatment groups. However, most of the SF-36 subscale scores were significantly better at this stage in the hysterectomy group than in the MRgFUS group. Women undergoing MRgFUS had steady improvement in all parameters throughout the 6-month follow-up period, despite the fact that they continued to have myomatous uteri and menstruation, which at baseline had given them significant symptomatology.
The results of this study show that MRgFUS treatment of uterine leiomyomas leads to clinical improvement with fewer significant clinical complications and adverse events compared to hysterectomy at 6 months' follow-up.
将接受磁共振引导聚焦超声(MRgFUS)治疗的女性与同期接受全子宫切除术的女性进行比较。报告患者的人口统计学数据、安全性参数、生活质量结果和残疾测量值。
在七个中心招募了 109 名接受 MRgFUS 治疗的女性,在七个单独的中心招募了 83 名接受全子宫切除术的女性,以提供同期安全性评估。前瞻性评估不良事件谱和残疾参数。患者还在基线和 1、3 和 6 个月使用 SF-36 健康调查问卷进行筛查。
两组均无危及生命的不良事件。总体而言,与接受子宫切除术的女性相比,MRgFUS 组发生重大临床并发症和不良事件的数量较低。MRgFUS 与更快的恢复相关,包括恢复正常活动。在 6 个月的随访中,MRgFUS 组有 4 例(4%)治疗失败。关于 SF-36 子量表评分,在 6 个月时,两组的所有 SF-36 子量表评分均有所改善。然而,在这个阶段,子宫切除术组的大多数 SF-36 子量表评分都明显好于 MRgFUS 组。接受 MRgFUS 的女性在整个 6 个月的随访期间,所有参数都在稳步改善,尽管她们仍然有子宫肌瘤和月经,这些在基线时给她们带来了显著的症状。
本研究结果表明,与子宫切除术相比,MRgFUS 治疗子宫肌瘤在 6 个月的随访中导致临床改善,且重大临床并发症和不良事件较少。